Page 50 - pesta2019_3-4

-pest-POSTEN Side 50

antibodies to the C6-peptide in Lyme neuro- nical Outcome of Lyme Neuroborreliosis in
borreliosis. J Infect. 2011 Feb;62:149-58. a High Endemic Area, 1995-2014: A Re-
5. Rupprecht TA et al.Diagnostic value of ce- trospective Cohort Study in Denmark.Clin
rebrospinal fluid CXCL13 for acute Lyme Infect Dis 2017; 65:1489-1495.
neuroborreliosis. A systematic review and 11. Bremell D et al. Cerebrospinal fluid CXCL13
meta-analysis. Clin Microbiol Infect. 2018 in Lyme neuroborreliosis and asymptomatic
Dec;24:1234-1240. HIV infection. BMC Neurol 2013; 13: 2.
6. Pietikäinen A et al.Point-of-care testing for 12. Hytönen J et al. CXCL13 and neopterin con-
CXCL13 in Lyme neuroborreliosis. Diag- centrations in cerebrospinal fluid of patients
nostic Microbiology & Infectious Disease, with Lyme neuroborreliosis and other disea-
2018;91:226-228. ses that cause neuroinflammation. Journal of
7. Pícha D et al.Prospective study on the che- Neuroinflammation 2014; 11:103
mokine CXCL13 in neuroborreliosis and 13. Van Burgel ND et al.Discriminating Lyme
other aseptic neuroinfections. Journal of the Neuroborreliosis from Other Neuroinflam-
Neurological Sciences, 2016;368:214-220 matory Diseases by Levels of CXCL13

8. Senel M et al, The chemokine CXCL13 in in Cerebrospinal Fluid. J Clin Microbiol.
acute neuroborreliosis. J Neurol Neurosurg 2011;49:2027-30
Psychiatry 2010;81:929-33
9. Ljøstad U et al, Clinical usefulness of intrat- Pasienten har samtykket til at historien publiseres.
hecal antibody testing in acute Lyme neuro-
borreliosis. Eur J Neurol. 2007 Aug;14:873-6 Ved Pascal Brügger-Synnes, overlege
infeksjonsavdeling Helse Møre og Romsdal,
10. Knudtzen FC et al, Characteristics and Cli- Ålesund sykehus